Florida Financial Advisors LLC Lowers Position in Gilead Sciences, Inc. $GILD

Posted by George Bondi on Jul 22nd, 2026

Gilead Sciences logo Florida Financial Advisors LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 89.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,846 shares of the biopharmaceutical company’s stock after selling 24,227 shares during the quarter. Florida Financial Advisors LLC’s holdings in Gilead Sciences were worth $397,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of GILD. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences during the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC increased its holdings in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new stake in shares of Gilead Sciences in the fourth quarter worth about $26,000. Wealth Preservation Advisors LLC lifted its position in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth about $28,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 2.2%

Shares of GILD stock opened at $130.28 on Wednesday. Gilead Sciences, Inc. has a 1 year low of $108.06 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The stock’s 50 day simple moving average is $129.63 and its two-hundred day simple moving average is $135.42. The company has a market cap of $161.75 billion, a PE ratio of 17.75 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the company earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts predict that Gilead Sciences, Inc. will post -0.77 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were given a $0.82 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the sale, the chief executive officer owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares of the company’s stock, valued at $15,395,077.28. This trade represents a 2.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 77,000 shares of company stock worth $9,978,740 over the last three months. 0.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have weighed in on GILD. Royal Bank Of Canada cut their price target on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a report on Wednesday, May 20th. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a report on Monday, July 6th. Finally, Citigroup boosted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $158.33.

View Our Latest Research Report on Gilead Sciences

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.